Jump to navigation Jump to search
Ambroxol structural formulae.png
Ambroxol ball-and-stick.png
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass378.10
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Ambroxol


Most recent articles on Ambroxol

Most cited articles on Ambroxol

Review articles on Ambroxol

Articles on Ambroxol in N Eng J Med, Lancet, BMJ


Powerpoint slides on Ambroxol

Images of Ambroxol

Photos of Ambroxol

Podcasts & MP3s on Ambroxol

Videos on Ambroxol

Evidence Based Medicine

Cochrane Collaboration on Ambroxol

Bandolier on Ambroxol

TRIP on Ambroxol

Clinical Trials

Ongoing Trials on Ambroxol at Clinical

Trial results on Ambroxol

Clinical Trials on Ambroxol at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Ambroxol

NICE Guidance on Ambroxol


FDA on Ambroxol

CDC on Ambroxol


Books on Ambroxol


Ambroxol in the news

Be alerted to news on Ambroxol

News trends on Ambroxol


Blogs on Ambroxol


Definitions of Ambroxol

Patient Resources / Community

Patient resources on Ambroxol

Discussion groups on Ambroxol

Patient Handouts on Ambroxol

Directions to Hospitals Treating Ambroxol

Risk calculators and risk factors for Ambroxol

Healthcare Provider Resources

Symptoms of Ambroxol

Causes & Risk Factors for Ambroxol

Diagnostic studies for Ambroxol

Treatment of Ambroxol

Continuing Medical Education (CME)

CME Programs on Ambroxol


Ambroxol en Espanol

Ambroxol en Francais


Ambroxol in the Marketplace

Patents on Ambroxol

Experimental / Informatics

List of terms related to Ambroxol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]


Ambroxol is a secretolytic agent used in the treatment of respiratory diseases associated with viscid or excessive mucus. It is the active ingredient of Mucosolvan, Mucobrox, Mucol, Lasolvan, Mucoangin, Surbronc, Ambolar, and Lysopain. The substance is a mucoactive drug with several properties including secretolytic and secretomotoric actions that restore the physiological clearance mechanisms of the respiratory tract, which play an important role in the body’s natural defence mechanisms. It stimulates synthesis and release of surfactant by type II pneumocytes. Surfactant acts as an anti-glue factor by reducing the adhesion of mucus to the bronchial wall, in improving its transport and in providing protection against infection and irritating agents.[1][2] Ambroxol is often administered as an active ingredient in cough syrup.

Ambroxol is indicated as "secretolytic therapy in bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport. It promotes mucus clearance, facilitates expectoration and eases productive cough, allowing patients to breathe freely and deeply".[3]

Ambroxol hydrochloride tablets in Japan

There are many different formulations developed since the first marketing authorisation in 1978. Ambroxol is available as syrup, tablets, pastilles, dry powder sachets, inhalation solution, drops and ampules as well as effervescent tablets.

Ambroxol also provides pain relief in acute sore throat. Pain in sore throat is the hallmark of acute pharyngitis.[4] Sore throat is usually caused by a viral infection. The infection is self limited and the patient recovers normally after a few days. What is most bothering for the patient is the continuous pain in the throat maximized when the patient is swallowing. The main goal of treatment is thus to reduce pain. The main property of Ambroxol for treating sore throat is the local anaesthetic effect, described first in the late 1970s,[5][6] but explained and confirmed in more recent work.

Ambroxol is a potent inhibitor of the neuronal Na+ channels.[7] This property led to the development of a lozenge containing 20 mg of ambroxol. Many state-of-the-art clinical studies[4] have demonstrated the efficacy of Ambroxol in relieving pain in acute sore throat, with a rapid onset of action, with its effect lasting at least three hours. Ambroxol is also anti-inflammatory, reducing redness in a sore throat.

Ambroxol has recently been shown to increase activity of the lysosomal enzyme glucocerebrosidase. Because of this it may be a useful therapeutic agent for both Gaucher disease and Parkinson's disease.[8]

Side effects

Field tests to date have not uncovered specific contraindications of Ambroxol. However, caution is suggested for patients with gastric ulceration, and usage during the first trimester of pregnancy is not recommended.[9]


Ambroxol synthesis.[10]


  1. Sanderson RJ et al. (1976), "Morphological and physical basis for lung surfactant action", Respir Phys, 27 (3): 379–92, doi:10.1016/0034-5687(76)90066-9, PMID 989610
  2. Kido H et al. (Nov 2004), "Secretory leukoprotease inhibitor and pulmonary surfactant serve as principal defenses against influenza A virus infection in the airway and chemical agents up-regulating their levels may have therapeutic potential.", Biol Chem, 385 (11): 1029–34, doi:10.1515/bc.2004.133, PMID 15576322
  3. Malerba M, Ragnoli B. (August 2008), "Ambroxol in the 21st century: pharmacological and clinical update", Expert Opin Drug Metab Toxicol., 4 (8): 1119–29, doi:10.1517/17425255.4.8.1119, PMID 18680446
  4. 4.0 4.1 de Mey C. et al. (2008), "Efficacy and safety of ambroxol lozenges in the treatment of acute uncomplicated sore throat", Arzneimittelforschung, 58 (11): 557–68, doi:10.1055/s-0031-1296557, PMID 19137906
  5. Püschmann S, Engelhorn R. (1978), "Pharmakologische Untersuchungen des Bromhexin-Metaboliten Ambroxol (Pharmacological study on the bromhexine-metabolite ambroxol)", Arzneimittelforschung, 28 (5a): 889–98, PMID 581987
  6. Klier KF, Papendick U. (1977), "Die lokalanaesthetische Wirkung von NA-872-haltigen Augentropfen (The local anesthetic effect of NA872-containing eyedrops)", Med Monatsschr., 31 (12): 575–8, PMID 593223
  7. Weiser T. (2006), "Comparison of the effects of four Na+ channel analgesics on TTX-resistant Na+ currents in rat sensory neurons and recombinant Nav1.2 channels", Neurosci Lett., 395 (3): 179–84, doi:10.1016/j.neulet.2005.10.058, PMID 16293367
  8. Alisdair McNeill et al. (2014), "Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells", Oxford Journals, 137 (5): 1481–1495, PMID 24574503
  9. [1], Ambroxol, accessed 21 January 2014

Template:Cough and cold preparations